Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eisai wins FDA approval for anesthesia drug
In the approval, the FDA required that Lusedra be used only by persons trained in the administration of general anesthesia and that all patients should be continuously monitored
In the approval, the FDA required that Lusedra be used only by persons trained in the administration of general anesthesia and that all patients should be continuously monitored
As a result of this ruling, the patent protection for this product is maintained in the US until November 2011. Sanofi-Aventis and Bristol-Myers Squibb are seeking damages from
Semprus is the developer of a new technology platform aimed at reducing medical device complications in areas of infections, thrombus, restenosis and bone integration. The company has previously
In 2004, based on results of Intergroup Exemestane Study the Team trial design was revised; the tamoxifen arm was converted into a tamoxifen/Aromasin sequencing arm. This analysis represents
The company has also announced that Lawrence Kenyon will join Par on December 15, 2008 as executive vice president of finance and will assume the role of CFO
According to the company, this represents the first and only approved Pegintron in combination with Rebetol for treating pediatric hepatitis C. Rebetol is available both as capsules and
The objectives of the double-blind, randomized, placebo-controlled multiple dose Phase Ib study were to determine safety and tolerance when adding ALX-0081 via intravenous administration to a standard anti-thrombotic
Ciprofloxacin HCl ophthalmic solution is indicated for the treatment of infections caused by microorganisms in corneal ulcers and conjunctivitis. Akorn expects to launch ciprofloxacin in 2009. Arthur Przybyl,
Isentress is approved for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-experienced adult patients who have evidence of viral replication and
BridgeGate has granted Healthation a non-exclusive license to incorporate the BridgeGate integration platform within Healthation’s AcceleHealth real-time benefit management system and AboveHealth EHealth suite. Healthation’s AcceleXchange, an integration